IUI With Letrozole Versus in Natural Cycle

Unexplained Infertility Clinical Trial

Official title:

Intrauterine Insemination With Letrozole Versus Intrauterine Insemination in Natural Cycle. A Muticenter Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04169451
• Other study ID #: IUI with/without stimulation
• Status: Recruiting
• Phase: N/A
• Start date: September 29, 2022
• Est. completion date: June 2026

Study information

• Verified date: February 2024
• Source: Peking University Third Hospital
• Contact: Shuo Huang
• Phone: 86-13601203410
• Email: homelyleaf[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale Intrauterine insemination (IUI) is the treatment of first choice for couples with unexplained and mild male factor infertility in many countries, but it is controversial whether ovarian stimulation improves fertility outcomes. In recent retrospectively collected data, we found that in couples with unexplained and mild male factor infertility undergoing IUI, ovarian stimulation with letrozole increased live birth rate as compared to natural cycle IUI without substantially increasing the multiple pregnancy rate. We therefore intend to perform a randomized clinical trial (RCT) on the subject in five reproductive medical centers in different cities in China. Objective To test the hypothesis that in couples with unexplained or mild male factor infertility scheduled for an IUI program ovarian stimulation with letrozole increases the live birth rate as compared to natural cycle treatment. Study design Multicenter randomized controlled trial. Study population Women diagnosed with unexplained or mild male factor infertility scheduled for treatment with IUI. Intervention Women will be randomized for ovarian stimulation with letrozole or to natural cycle IUI. In the group allocated to ovarian stimulation, women will receive oral tablets letrozole 5 mg daily from cycle day 3 for 5 days. We will treat the couples for 3 cycles, with a time horizon of 4 months. Main study parameters/endpoints Primary outcome is live birth resulting from conception within 4 months after randomization. Secondary endpoints are clinical pregnancy, multiple pregnancy, miscarriage rates, pregnancy complications, time to pregnancy leading to live birth. Nature and extent of the burden and risks associated with participation, benefit and group relatedness The strategies compared are already broadly applied in current practice. No additional risks are expected. There is no benefit for participants, but the results may benefit future infertile couples.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 982
• Est. completion date: June 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion criteria In order to be eligible to participate in this study, a participating couple must meet all

of the following criteria:

• Being diagnosed with unexplained or mild male infertility
• At least one sided tubal patency, established according to local protocol
• Normal or mild impairment of semen quality defined as total motile sperm count (TMSC) no less than 5million, based on at least one recent semen analysis Exclusion criteria A potential participant who meets any of the following criteria will be excluded from study

participation:

• Woman with double sided tubal pathology
• Women with irregular cycles, PCOS or other endocrine disorders
• Man with impaired semen quality: total motile sperm count (TMSC) less than 5million

Related Conditions & MeSH terms

• Infertility
• Intrauterine Insemination
• Unexplained Infertility

Intervention

Drug:
• Letrozole
Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (5)

Lead Sponsor	Collaborator
Peking University Third Hospital	The 1st Affiliated Hospital of Anhui Medical University, The 2nd Affiliated Hospital of Hebei Medical University, Tianjin Central Hospitalof Gynecology Obstetrics, Yunnan1stpeople's hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	live birth rate	Primary outcome is live birth resulting from conception within 4 months after randomization.	14 months